GlycoMimetics Inc (GLYC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

GlycoMimetics Inc (GLYC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH141235D
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

GlycoMimetics Inc (GlycoMimetics) is a clinical-stage biotechnology company that research, develops and commercializes small molecule drugs. The company's products comprise rivipansel (GMI-1070), under phase III clinical trial is an anti-inflammatory compound to treat vaso-occlusive crisis of sickle cell disease and blood cancers. It also provides GMI-1271, galectin inhibitors, GMI-1359, GMI-1051 and research programs. GlycoMimetics designs and tests viral and bacterial entry inhibitors dendritic cell receptor. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

GlycoMimetics Inc (GLYC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11

Licensing Agreements 12

GlycoMimetics Enters Into Licensing Agreement With Pfizer For GMI-1070 12

Equity Offering 14

GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14

GlycoMimetics Raises USD21 Million in Public Offering of Shares 16

GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18

GlycoMimetics Completes IPO For USD64.4 Million 19

GlycoMimetics Inc-Key Competitors 21

GlycoMimetics Inc-Key Employees 22

GlycoMimetics Inc-Locations And Subsidiaries 23

Head Office 23

Recent Developments 24

Financial Announcements 24

Aug 03, 2017: GlycoMimetics Reports Program Updates and Second Quarter 2017 Results 24

May 08, 2017: GlycoMimetics Reports Program Updates and First Quarter 2017 Results 26

Mar 01, 2017: GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results 27

Nov 04, 2016: GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development 28

Aug 04, 2016: GlycoMimetics Reports Second Quarter 2016 Results 30

May 04, 2016: GlycoMimetics Reports First Quarter 2016 Results 31

Feb 29, 2016: GlycoMimetics Reports Fourth Quarter and Year-End 2015 Results 32

Corporate Communications 33

Jun 12, 2017: GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors 33

Mar 13, 2017: GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors 34

Mar 21, 2016: GlycoMimetics Appoints ImmunoGen CEO Daniel Junius to Board of Directors 35

Product News 36

12/05/2016: GlycoMimetics GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML 36

06/10/2016: GlycoMimetics GMI-1271 Yields High Remission Rates and Favorable Tolerability in Phase 1 Portion of Phase 1/2 Clinical Trial for AML 37

05/19/2016: Initial Efficacy Data for GlycoMimetics' GMI-1271 Combined with Chemotherapy in Patients with AML to Be Presented at European Hematology Association 21st Congress 38

03/02/2016: GlycoMimetics Announces Initial Clinical Data from Phase 1 Portion of Clinical Trial of GMI-1271 in AML Patients 39

Product Approvals 40

Jun 13, 2016: GlycoMimetics' GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia 40

May 25, 2016: GlycoMimetics plans to file IND application for GMI-1359 41

Clinical Trials 42

Mar 07, 2017: GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271 42

Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1271 at AACR Annual Meeting 2017 43

Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017 44

Nov 08, 2016: GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting 45

Sep 14, 2016: GlycoMimetics Doses First Patient in Phase 1 Clinical Trial of Drug Candidate GMI-1271 for Multiple Myeloma 46

Sep 06, 2016: GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359 47

Aug 16, 2016: GlycoMimetics Announces Publication of Preclinical Data Showing Drug Candidate GMI-1271 Reduces Inflammatory Responses After Heart Attack 48

Jun 06, 2016: GlycoMimetics Doses First Patient in Phase 2 Portion of GMI-1271 Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia 49

May 25, 2016: GlycoMimetics Announces Publication of New Preclinical Data with GMI-1271 in Science Translational Medicine 50

Apr 25, 2016: GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference 51

Mar 17, 2016: GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016 52

Appendix 53

Methodology 53

About GlobalData 53

Contact Us 53

Disclaimer 53

List of Figures

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

GlycoMimetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

GlycoMimetics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

GlycoMimetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

IAVI, GlycoMimetics, And Glycosensors and Diagnostics Enter Into Agreement To Develop AIDS Vaccine 11

GlycoMimetics Enters Into Licensing Agreement With Pfizer For GMI-1070 12

GlycoMimetics Raises USD92.6 Million in Public Offering of Shares 14

GlycoMimetics Raises USD21 Million in Public Offering of Shares 16

GlycoMimetics Raises USD3 Million in First Tranche of Public Offering of Shares 18

GlycoMimetics Completes IPO For USD64.4 Million 19

GlycoMimetics Inc, Key Competitors 21

GlycoMimetics Inc, Key Employees 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

GlycoMimetics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16190
Site License
USD 500 INR 32380
Corporate User License
USD 750 INR 48570

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com